FluoGuide A/S (FLUO)
XSTO XSTO Primary Summary
FluoGuide A/S (FLUO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has FluoGuide A/S ever had a stock split?
FluoGuide A/S Profile
| Biotechnology Industry | Healthcare Sector | Mr. Morten Albrechtsen B.B.A., BBA, M.D. CEO | XSTO Exchange | DK0061123312 ISIN |
| SE Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
FluoGuide A/S is a pioneering clinical stage biotechnology entity based in Copenhagen, Denmark, that concentrates on enhancing surgical outcomes by making cancer visible through fluorescence. Established in 2018, FluoGuide's innovative approach targets the improvement of precision in surgical procedures, potentially leading to better prognoses for patients. Through strategic collaborations with institutions like Linköping University Hospital, Copenhagen University Hospital, and companies such as Intuitive Surgical, Inc., FluoGuide is at the forefront of integrating luminescent technology with surgical practices, especially in the realm of robotics surgery.
Products and Services
- FG001
- FG002
FG001 stands as FluoGuide's prime product candidate, currently navigating through various phases of clinical trials. This product aims to revolutionize the treatment of several cancer types, including high-grade glioma (in Phase IIa and IIb trials), lung cancer, and head and neck cancer (both in Phase II trials). By making cancer cells fluoresce, FG001 offers surgeons an unprecedented level of visibility during surgery, potentially increasing the accuracy of tumor removal.
In its preclinical stage, FG002 represents FluoGuide's next innovative stride towards refining surgical precision. Utilizing a novel uPAR-targeted luminescent technology, FG002 is designed to illuminate the fine line between cancerous tissues and healthy tissues, thus enabling surgeons to perform more precise and safe operations. The development of FG002 demonstrates FluoGuide's commitment to expanding its portfolio of fluorescence-guided surgery solutions.
